Johnson & Johnson (NYSE:JNJ) Shares Down 0.2% – Here’s Why

Johnson & Johnson (NYSE:JNJ) shares dropped 0.2% during trading on Tuesday . The stock traded as low as $148.33 and last traded at $149.25. Approximately 2,521,903 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 7,066,104 shares. The stock had previously closed at $149.60.

Analyst Ratings Changes

JNJ has been the subject of several recent research reports. Bank of America reissued a “neutral” rating and issued a $166.00 price target on shares of Johnson & Johnson in a research report on Tuesday. Citigroup boosted their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, Guggenheim boosted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $175.40.

Johnson & Johnson Trading Up 0.1 %

The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a 50 day simple moving average of $157.84 and a two-hundred day simple moving average of $156.40. The firm has a market cap of $360.42 billion, a PE ratio of 21.60, a P/E/G ratio of 2.65 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 EPS. Analysts expect that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.31%. Johnson & Johnson’s payout ratio is 71.78%.

Institutional Trading of Johnson & Johnson

A number of hedge funds have recently modified their holdings of the stock. DGS Capital Management LLC boosted its stake in shares of Johnson & Johnson by 17.5% in the third quarter. DGS Capital Management LLC now owns 5,404 shares of the company’s stock worth $876,000 after buying an additional 804 shares during the last quarter. Copley Financial Group Inc. purchased a new stake in shares of Johnson & Johnson in the third quarter worth about $676,000. Retirement Systems of Alabama boosted its stake in shares of Johnson & Johnson by 4.0% in the third quarter. Retirement Systems of Alabama now owns 1,243,090 shares of the company’s stock worth $201,455,000 after buying an additional 48,250 shares during the last quarter. Oddo BHF Asset Management Sas purchased a new stake in shares of Johnson & Johnson in the third quarter worth about $406,000. Finally, Inspire Trust Co. N.A. boosted its stake in shares of Johnson & Johnson by 12.2% in the third quarter. Inspire Trust Co. N.A. now owns 24,063 shares of the company’s stock worth $3,900,000 after buying an additional 2,610 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.